Last reviewed · How we verify

paracetamol / ondansetron

University Hospital, Limoges · Phase 3 active Small molecule

Paracetamol acts as a non-selective inhibitor of cyclooxygenase enzymes, reducing prostaglandin synthesis and thereby decreasing pain and fever. Ondansetron acts as a selective serotonin 5-HT3 receptor antagonist, inhibiting the action of serotonin and reducing nausea and vomiting.

Paracetamol acts as a non-selective inhibitor of cyclooxygenase enzymes, reducing prostaglandin synthesis and thereby decreasing pain and fever. Ondansetron acts as a selective serotonin 5-HT3 receptor antagonist, inhibiting the action of serotonin and reducing nausea and vomiting. Used for Treatment of pain and fever, Prevention of nausea and vomiting caused by chemotherapy, radiation therapy, and surgery.

At a glance

Generic nameparacetamol / ondansetron
SponsorUniversity Hospital, Limoges
Drug classNon-opioid analgesic and antiemetic
TargetCyclooxygenase enzymes and 5-HT3 receptors
ModalitySmall molecule
Therapeutic areaPain management and nausea/vomiting prevention
PhasePhase 3

Mechanism of action

Paracetamol's mechanism of action is thought to involve the inhibition of prostaglandin synthesis through the inhibition of cyclooxygenase enzymes, which are involved in the production of prostaglandins. This reduction in prostaglandin synthesis leads to a decrease in pain and fever. Ondansetron, on the other hand, acts as a selective serotonin 5-HT3 receptor antagonist, which prevents the action of serotonin on the 5-HT3 receptors in the central nervous system, thereby reducing nausea and vomiting.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results